Healthcare provider profile · identity verified

Rafael Jose Collazo, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine · SAN GERMAN, PR · NPI 1215348321

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Rafael Jose Collazo, M.D. received $52.59 in general payments during 2025 across 2 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 58.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Farxiga by this doctor in 2024.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synjardy by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$52.59

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$30.66	58.3%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$21.93	41.7%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$52.59	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$30.66	1	2025
Source payment records 2025-10-21 · Boehringer Ingelheim Pharmaceuticals, Inc. · $30.66 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	22 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	40	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	121	33
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	22	suppressed by CMS
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	SYNJARDY open payments reported associated product	CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005	Synjardy · 2024 Exact normalized brand match · 1 Part D row	23	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Famotidine	Famotidine	1000	219
Simvastatin	Simvastatin	933	197
Losartan Potassium	Losartan Potassium	733	171
Gabapentin	Gabapentin	716	159
Levothyroxine Sodium	Levothyroxine Sodium	637	151
Atorvastatin Calcium	Atorvastatin Calcium	564	143
Amlodipine Besylate	Amlodipine Besylate	485	126
Omeprazole	Omeprazole	442	94
Metformin Hcl	Metformin Hcl	385	76
Lisinopril	Lisinopril	348	78
Rosuvastatin Calcium	Rosuvastatin Calcium	308	72
Tamsulosin Hcl	Tamsulosin Hcl	307	84
Ezetimibe	Ezetimibe	285	58
Metoprolol Succinate	Metoprolol Succinate	279	69
Alendronate Sodium	Alendronate Sodium	261	70
Clonazepam	Clonazepam	253	52
Clopidogrel	Clopidogrel Bisulfate	246	76
Pantoprazole Sodium	Pantoprazole Sodium	239	68
Glimepiride	Glimepiride	233	51
Synthroid	Levothyroxine Sodium	233	57
Isosorbide Mononitrate Er	Isosorbide Mononitrate	227	57
Carvedilol	Carvedilol	201	51
Fluticasone Propionate	Fluticasone Propionate	188	109
Glipizide	Glipizide	184	35
Hydrochlorothiazide	Hydrochlorothiazide	174	40
Lansoprazole	Lansoprazole	174	33
Diclofenac Sodium	Diclofenac Sodium	169	87
Atenolol	Atenolol	167	31
Nifedipine Er	Nifedipine	164	42
Doxazosin Mesylate	Doxazosin Mesylate	156	46
Finasteride	Finasteride	150	37
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	138	35
Fenofibrate	Fenofibrate	136	24
Enalapril Maleate	Enalapril Maleate	135	28
Bumetanide	Bumetanide	127	39
Farxiga	Dapagliflozin Propanediol	121	33
Esomeprazole Magnesium	Esomeprazole Magnesium	117	27
Etodolac Er	Etodolac	111	75
Xarelto	Rivaroxaban	105	29
Hydralazine Hcl	Hydralazine Hcl	102	24
Temazepam	Temazepam	100	16
Montelukast Sodium	Montelukast Sodium	99	27
Furosemide	Furosemide	93	26
Alprazolam	Alprazolam	92	19
Levofloxacin	Levofloxacin	92	76
Azithromycin	Azithromycin	88	75
Metoprolol Tartrate	Metoprolol Tartrate	88	28
Meloxicam	Meloxicam	85	25
Sucralfate	Sucralfate	82	33
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	80	15
Allopurinol	Allopurinol	77	19
Pregabalin	Pregabalin	76	11
Eliquis	Apixaban	75	16
Irbesartan	Irbesartan	75	22
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	74	50
Lantus	Insulin Glargine,hum.Rec.Anlog	74	19
Diclofenac Sodium Er	Diclofenac Sodium	71	25
Escitalopram Oxalate	Escitalopram Oxalate	70	20
Latanoprost	Latanoprost	69	17
Glipizide Er	Glipizide	66	18
Spironolactone	Spironolactone	66	26
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	65	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	63	27
Cilostazol	Cilostazol	58	13
Donepezil Hcl	Donepezil Hcl	53	16
Levoxyl	Levothyroxine Sodium	53	13
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	52	40
Janumet Xr	Sitagliptin Phos/Metformin Hcl	49	suppressed
Pravastatin Sodium	Pravastatin Sodium	48	11
Wixela Inhub	Fluticasone Propion/Salmeterol	47	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	44	suppressed
Trijardy Xr	Empaglifloz/Linaglip/Metformin	44	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	42	suppressed
Propranolol Hcl	Propranolol Hcl	41	suppressed
Brilinta	Ticagrelor	40	suppressed
Metformin Hcl Er	Metformin Hcl	40	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	39	suppressed
Raloxifene Hcl	Raloxifene Hcl	39	suppressed
Sertraline Hcl	Sertraline Hcl	38	11
Meclizine Hcl	Meclizine Hcl	37	24
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	37	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	36	15
Digoxin	Digoxin	36	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	35	suppressed
Lorazepam	Lorazepam	35	suppressed
Baclofen	Baclofen	34	22
Diclofenac Potassium	Diclofenac Potassium	34	21
Tizanidine Hcl	Tizanidine Hcl	34	24
Pen Needle	Pen Needle, Diabetic	32	14
Albuterol Sulfate Hfa	Albuterol Sulfate	31	14
Lactulose	Lactulose	31	20
Lumigan	Bimatoprost	31	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Tramadol Hcl	Tramadol Hcl	30	14
Sildenafil Citrate	Sildenafil Citrate	29	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	28	16
Memantine Hcl	Memantine Hcl	27	suppressed
Nitroglycerin Patch	Nitroglycerin	27	15
Nabumetone	Nabumetone	26	suppressed
Chlorthalidone	Chlorthalidone	25	suppressed
Trazodone Hcl	Trazodone Hcl	25	suppressed
Valsartan	Valsartan	25	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	24	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	23	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	23	suppressed
Synjardy	Empagliflozin/Metformin Hcl	23	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	22	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	22	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	22	suppressed
Jardiance	Empagliflozin	22	suppressed
Nitroglycerin	Nitroglycerin	22	16
Terazosin Hcl	Terazosin Hcl	22	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	22	suppressed
Etodolac	Etodolac	21	13
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Pentoxifylline	Pentoxifylline	21	suppressed
Warfarin Sodium	Warfarin Sodium	21	suppressed
Amiodarone Hcl	Amiodarone Hcl	20	suppressed
Elmiron	Pentosan Polysulfate Sodium	20	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	20	suppressed
Acetic Acid	Acetic Acid	19	15
Clindamycin Hcl	Clindamycin Hcl	18	17
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	17	suppressed
Humulin R	Insulin Regular, Human	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Ranolazine Er	Ranolazine	16	suppressed
Timolol Maleate	Timolol Maleate	16	suppressed
Cefadroxil	Cefadroxil	15	15
Ciclopirox	Ciclopirox	15	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Dexlansoprazole Dr	Dexlansoprazole	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Galantamine Er	Galantamine Hbr	14	suppressed
Levo-T	Levothyroxine Sodium	14	suppressed
Prednisone	Prednisone	14	suppressed
Synjardy Xr	Empagliflozin/Metformin Hcl	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Fluconazole	Fluconazole	13	12
Fluticasone Propionate Hfa	Fluticasone Propionate	13	suppressed
Ibu	Ibuprofen	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	12
Propylthiouracil	Propylthiouracil	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Verapamil Sr	Verapamil Hcl	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Carbamazepine Er	Carbamazepine	12	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	11
Ibuprofen	Ibuprofen	12	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	12	suppressed
Methylprednisolone	Methylprednisolone	12	11
Metronidazole	Metronidazole	12	12
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Ramipril	Ramipril	12	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	11	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	11	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Dutasteride	Dutasteride	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$52.59 · 2 records	Boehringer Ingelheim Pharmaceuticals, Inc.	JARDIANCE	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error